Skip to content
Calculator
Evidence: HighPeptide conjugateFDA ApprovedRadiolabelled peptideFDA-approved 2019 · Ga 68 DOTATOCLu-177 therapy in trials

Edotreotide

A somatostatin analogue for neuroendocrine tumour imaging and therapy

Edotreotide, better known as DOTATOC, is a somatostatin analogue joined to a DOTA chelator. Loaded with gallium-68 it is an FDA-approved PET tracer for neuroendocrine tumours; loaded with lutetium-177 it is an investigational radioligand therapy, with a meta-analysis reporting disease control in 78% of gastroenteropancreatic tumours.

Manufacturer's recommended dosing (FDA label): 148 MBq (4 mCi), Single bolus, Intravenous Details ↓

Overview

What is it?

Edotreotide is the octreotide-based relative of dotatate. Both bind somatostatin receptors on neuroendocrine tumours, and both can carry a diagnostic or therapeutic radionuclide. FDA approved Ga 68 DOTATOC injection, made by the UIHC PET Imaging Center, on August 21, 2019, for adults and children. In a study of patients with suspected or metastatic neuroendocrine tumours, gallium-68 DOTATOC had a sensitivity of 88% against 41% for FDG PET and 53% for conventional workup, with 100% specificity.

With lutetium-177, it becomes a treatment. A 2026 meta-analysis of eight studies in advanced disease found objective responses in 34% and disease control in 78% of patients with gastroenteropancreatic tumours, with median progression-free survival of 24.9 months and overall survival of 44.8 months; grade 3 or 4 toxicity was rarely reported, though heterogeneity was high. Randomised trials, including LEVEL in lung and thymic tumours, are testing it against standard treatments.

The first randomised phase 3 trial of the treatment form has now reported. In COMPETE, 309 people with progressive grade 1 or 2 gastroenteropancreatic neuroendocrine tumours were assigned to lutetium-177 edotreotide (about 7.5 GBq every three months, up to four cycles) or daily everolimus tablets. Median progression-free survival was 23.9 months against 14.1 months, a 33% lower risk of progression, and grade 3 or 4 treatment-related side effects were less common (18% against 40%). Diarrhoea, nausea and tiredness were the commonest side effects of the radiotherapy.

The label for the gallium-68 form lists radiation risk, hypersensitivity reactions and a risk of image misinterpretation, and says to image just before a dose of long-acting somatostatin analogue because these compete for the same receptors.

In Europe, a kit for preparing gallium-68 edotreotide, SomaKit TOC, has been authorised since 2016, while a marketing application for the lutetium-177 treatment, Luveniq, was withdrawn, according to the European Medicines Agency's records. In the US only the gallium-68 imaging form is approved.

The open questions are about sequence and comparison. COMPETE showed the radiotherapy beat everolimus, a targeted tablet, as a treatment choice; it did not compare lutetium-177 edotreotide with lutetium-177 dotatate, the radioligand already approved in the US, and overall survival data are still maturing. The LEVEL trial is testing it in lung and thymic tumours, where the evidence is thinnest.

Newer imaging studies show why the gallium-68 form has largely replaced the older indium-111 octreotide scan. Imaged both ways, 115 patients scored higher on PET, and the share eligible for radioligand therapy under trial criteria rose from about half to about three quarters. The total receptor-positive tumour volume on PET, rather than the single hottest spot, predicted how long the disease stayed controlled. Outside neuroendocrine tumours the picture is mixed: uptake guided dosing of yttrium-90 DOTATOC in a small series of refractory meningiomas, but in metastatic breast cancer it was weak and FDG PET did better.

23.9 vs 14.1 mo
progression-free survival vs everolimus
COMPETE, 309 patients (2026) · PMID 42392118
18% vs 40%
grade 3–4 treatment-related events
COMPETE · PMID 42392118
88% vs 41%
sensitivity vs FDG PET
gallium-68 imaging, 36 patients (2018) · PMID 28735662
148 MBq
adult imaging dose
Ga 68 DOTATOC label
Science

Mechanism of Action

Edotreotide is octreotide fitted with a DOTA cage: the octreotide finds somatostatin receptors on tumours, and the cage carries either an imaging or a treatment radionuclide.

🎯

Somatostatin receptor 2

Like octreotide, it binds somatostatin receptors, especially type 2, which most well-differentiated neuroendocrine tumours carry in large numbers.

📷

Gallium-68 for PET

With gallium-68 it lights up receptor-positive tumours on a PET scan; the label times imaging 55 to 90 minutes after the injection.

☢️

Lutetium-177 for treatment

With lutetium-177, beta radiation damages the tumour cells that take it up; this is the form tested in COMPETE.

⏱

Competing with long-acting analogues

Long-acting somatostatin analogues block the same receptors, so the label advises imaging just before their next dose.

Evidence

Published Research

Studies of edotreotide (DOTATOC), from their PubMed abstracts.

Human2026

Lutetium-177 edotreotide meta-analysis

Across eight studies in advanced neuroendocrine tumours, patients with gastroenteropancreatic tumours had objective response 34%, disease control 78%, median PFS 24.9 months and median OS 44.8 months; grade 3/4 toxicity was rare, but heterogeneity was high.

PMID: 41204752
Human2018

Gallium-68 DOTATOC vs FDG PET

In 36 patients, sensitivity was 88% for gallium-68 DOTATOC, 41% for FDG PET and 53% for conventional workup, with specificity of 100%, 100% and 68%.

PMID: 28735662
Human2025

LEVEL trial design

The randomised LEVEL trial (NCT05918302) is testing whether lutetium-177 edotreotide improves survival and quality of life in neuroendocrine tumours of the lung and thymus.

PMID: 40186126
Human2020

Lutetium-177 DOTATATE/DOTATOC meta-analysis

Across 22 studies of 1,758 patients with advanced neuroendocrine tumours, pooled disease response rates for lutetium-177 DOTATATE or DOTATOC were about 33% to 35% depending on response criteria.

PMID: 32150065
Human2021

Terbium-161 DOTATOC first in humans

Terbium-161, which decays like lutetium-177 but also emits conversion and Auger electrons, was used to label DOTATOC and imaged in patients to test the feasibility of a next-generation radioligand.

PMID: 33547209
Human2017

Against copper-64 dotatate

In 59 patients scanned with both, 83% of the additional true lesions found by only one scan came from copper-64 DOTATATE rather than gallium-68 DOTATOC (33 against 7).

PMID: 27660147
Human2026

COMPETE phase 3: against everolimus

In 309 patients with progressive grade 1-2 GEP neuroendocrine tumours, lutetium-177 edotreotide gave median progression-free survival of 23.9 months against 14.1 with everolimus (hazard ratio 0.67); treatment-related grade 3-4 events affected 18% against 40%.

PMID: 42392118
Human2026

PET against the older octreotide scan

In 115 people with neuroendocrine tumours imaged both ways, gallium-68 DOTATOC PET gave higher Krenning uptake scores than indium-111 octreotide scintigraphy, raising eligibility for radioligand therapy under NETTER-1 criteria from 59.1% to 81.7% and under NETTER-2 criteria from 48.7% to 76.5%.

PMID: 42284283
Human2026

Tumour volume on PET predicts outcome

In 60 patients with metastatic gastroenteropancreatic neuroendocrine tumours, the somatostatin-receptor tumour volume measured on gallium-68 edotreotide PET predicted progression-free survival, while the single hottest spot (SUVmax) did not.

PMID: 41572131
Human2026

Yttrium-90 DOTATOC in refractory meningioma

In 10 patients with meningioma that had failed surgery and radiotherapy, uptake on the pre-treatment gallium-68 DOTATOC scan correlated with the radiation dose each lesion absorbed from yttrium-90 DOTATOC; median overall survival was 23.0 months in this small retrospective series.

PMID: 42554825
Human2026

Breast cancer imaging

In metastatic breast cancer, gallium-68 DOTATOC uptake was mostly moderate in oestrogen-receptor-positive disease and low in triple-negative disease, and FDG PET outperformed it; only one patient reached the uptake level that makes radioligand therapy technically possible.

PMID: 42350034
Human2010

Yttrium-90 therapy for refractory carcinoid

In a 90-patient phase 2 trial in metastatic carcinoid no longer controlled by octreotide, three cycles of yttrium-90 edotreotide six weeks apart left 74% stable or responding and improved all 12 symptoms assessed; adverse events, mostly reversible gastrointestinal effects partly from the kidney-protecting amino-acid infusion, occurred in 97%, with one case each of grade 3 oliguria and grade 4 kidney failure.

PMID: 20194865
Human2009

Radiation dose of a gallium-68 scan

In 14 patients scanned with gallium-68 DOTATOC, the effective dose was 0.023 mSv per MBq injected, the spleen and kidneys received the most, the tracer left only in urine (16% within two hours), and the CT used for correction added up to 1 mSv.

PMID: 19639164
Human2017

Screening in MEN1: limited value

In 33 patients with multiple endocrine neoplasia type 1, gallium-68 DOTATOC PET-CT found 55 neuroendocrine tumours where conventional imaging found 145, missing every lesion under 5 mm and 71% of those 5-9 mm; it changed management in one patient, and the authors advise against it for routine screening.

PMID: 28138732
Human2024

Metastases beyond the liver: 1,177 patients

Reviewing the PET-CT reports of 1,177 patients with small-intestinal or pancreatic neuroendocrine tumours, lesions outside the liver and abdominal nodes appeared in 26%, bone metastases in 18.4%, and extra-abdominal or pancreatic spread more often with small-intestinal tumours (34%) than pancreatic ones (13%).

PMID: 38590270
Human2025

Pituitary tumours in Cushing's disease

In 30 patients with Cushing's disease, gallium-68 DOTATOC PET/CT located 77% of the ACTH-secreting adenomas, no better than MRI; success was predicted by a preoperative ACTH level above about 54 pg/mL.

PMID: 40101328
Review2025

False positives: a systematic review

A systematic review of 42 studies (601 patients) catalogued 219 false-positive gallium-68 DOTATOC findings: half from non-cancerous conditions, 27% from benign tumours and 22% from other cancers, most often in the abdomen, bones, and head and neck.

PMID: 41058218
Dosing

Dosing Data

In the US, edotreotide is used only as the gallium-68 PET imaging agent; doses below are the label's imaging doses, with the trial dose of the treatment form for comparison.

Given in nuclear medicine departments under radiation-safety rules; the treatment form is not approved in the US.
ProtocolDoseFrequencyDurationRoute
Label: Ga 68 DOTATOC imaging, adults Approved labelGa 68 DOTATOC (gallium Ga 68 edotreotide) injection US prescribing information, section 2 (DailyMed set c4d185c3, effective December 8, 2021)148 MBq (4 mCi)Single bolusOnce, imaging at 55–90 minutesIntravenous
Label: Ga 68 DOTATOC imaging, children Approved labelGa 68 DOTATOC (gallium Ga 68 edotreotide) injection US prescribing information, section 2 (DailyMed set c4d185c3, effective December 8, 2021)1.59 MBq/kg (11.1 to 111 MBq)Single bolusOnceIntravenous
COMPETE treatment (2026) Human studyPMID 42392118About 7.5 GBq lutetium-177 edotreotideEvery 3 monthsUp to 4 cyclesIntravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Measured in becquerels
Doses are radioactivity, prepared by a radiopharmacy and given once by a nuclear medicine team; there is nothing to reconstitute.
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Ga-68-dotatoc (edotreotide gallium ga-68 injection): Injection: 18.5 MBq/mL to 148 MBq/mL (0.5 mCi/mL to 4 mCi/mL) of Ga 68 DOTATOC Injection in a multiple-dose glass vial. Forms the label lists: multiple-dose vials.

Source: Ga-68-dotatoc (edotreotide gallium ga-68 injection) label, section 3 (DailyMed version 3, effective December 8, 2021).

Mixing a vial: a worked example

Nothing to mix at home, and no syringe units to work out: Edotreotide is a radioactive drug, prepared and given in nuclear-medicine departments, and its dose is an amount of radioactivity (MBq or GBq), not a weight.

This page's dosing note: “Doses are radioactivity, prepared by a radiopharmacy and given once by a nuclear medicine team; there is nothing to reconstitute.”

Its label says: “Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.”

Source: this page's own note in Dosing Data below; Ga-68-dotatoc (edotreotide gallium ga-68 injection) label, section 2 (DailyMed version 3, effective December 8, 2021); the amount of each dose row in Dosing Data below.

Storage before and after mixing

Before mixing or first use: “Store Ga 68 DOTATOC Injection upright in a lead shielded container at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).” “Store and dispose of Ga 68 DOTATOC Injection in accordance with the regulations and a general license, or its equivalent, of an Agreement State or a Licensing State.”

After mixing or first use: the label sentences we read say nothing separate about this.

Source: Ga-68-dotatoc (edotreotide gallium ga-68 injection) label, sections 16 and 2 (DailyMed version 3, effective December 8, 2021).

How it is taken

As the approved label gives it: Intravenous (Single bolus; Label: Ga 68 DOTATOC imaging, adults).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Label: Ga 68 DOTATOC imaging, adults: Once, imaging at 55–90 minutes; Label: Ga 68 DOTATOC imaging, children: Once.

When effects appear: unknown; no source on this page gives a time to effect for Edotreotide. Results reported in the studies are under Published Research.

Source: Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Grade 3/4 toxicity rarely reported with lutetium-177 edotreotide; In COMPETE, diarrhoea and nausea (each 36%) and asthenia (33%) were the commonest treatment-related effects of lutetium-177 edotreotide; Everolimus caused more grade 3-4 effects than the radiotherapy in COMPETE (40% against 18%). Full list and cautions ↓

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Edotreotide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the studies above”).

Interactions

  • long-acting somatostatin analogues: compete for the same receptors; image just before the next long-acting dose
  • short-acting somatostatin analogues: can be used up to 24 hours before imaging

Every peptide's record, with its source: the interaction matrix.

Source: UIHC PET Imaging Center. Ga 68 DOTATOC (gallium Ga 68 edotreotide) injection US prescribing information, section 7. DailyMed version of December 8, 2021, read October 3, 2026.

Checking what you bought

Unknown: no published independent test of Edotreotide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved. Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Grade 3/4 toxicity rarely reported with lutetium-177 edotreotide
● In COMPETE, diarrhoea and nausea (each 36%) and asthenia (33%) were the commonest treatment-related effects of lutetium-177 edotreotide
● Everolimus caused more grade 3-4 effects than the radiotherapy in COMPETE (40% against 18%)

Contraindications & Cautions

Warnings from the Ga 68 DOTATOC label (DailyMed, effective December 8, 2021).

● Radiation risk
● Hypersensitivity reactions
● Risk of image misinterpretation
Questions

Frequently Asked Questions

?What is the difference between DOTATOC and DOTATATE?

Both are DOTA-linked somatostatin analogues that bind receptors on neuroendocrine tumours, and each is approved in the US with gallium-68 for PET imaging. A 2017 head-to-head study found copper-64 dotatate detected more true lesions than gallium-68 DOTATOC.

?Is lutetium-177 edotreotide approved?

No. It is investigational; a 2026 meta-analysis reported disease control in 78% of gastroenteropancreatic tumours, and randomised trials are ongoing.

?Should somatostatin analogue injections be paused before the scan?

The label says to image just before a dose of long-acting analogue; short-acting analogues can be used up to 24 hours before imaging.

?What dose is used for the scan?

The label recommends 148 MBq for adults and 1.59 MBq/kg for children (11.1 to 111 MBq), as an intravenous bolus, with imaging 55 to 90 minutes later.

?Is lutetium-177 edotreotide approved?

Not in the US or EU as of October 2026. Its phase 3 COMPETE trial beat everolimus on progression-free survival, and a European application under the name Luveniq was withdrawn.

?How does edotreotide differ from dotatate?

Both are somatostatin analogues fitted with a DOTA cage and used for imaging and treatment. Edotreotide is built on octreotide; dotatate on the closely related octreotate. In a 2017 head-to-head imaging study, copper-64 dotatate found more of the extra lesions than gallium-68 edotreotide.

?Who is the gallium-68 scan for?

Adults and children with known or suspected somatostatin receptor-positive neuroendocrine tumours, to locate them; in a 36-patient study it found tumours FDG PET missed (sensitivity 88% against 41%).

?What are the side effects of the scan?

The gallium-68 label lists radiation risk, hypersensitivity reactions and a risk of misreading images; the dose is a single small injection given before PET imaging.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): GALLIUM GA 68 EDOTREOTIDE (Ga-68-DOTATOC), NDA 210828, UIHC PET Imaging Center (August 21, 2019). Read October 3, 2026.
  2. [fda-pi] FDA. Ga 68 DOTATOC (gallium Ga 68 edotreotide) injection US prescribing information (UIHC PET Imaging Center; DailyMed set c4d185c3-d520-462d-ba50-4f4ee485ace3, version 3, effective December 8, 2021). Read October 3, 2026.
  3. [other] EMA medicines dataset: SomaKit TOC (edotreotide), authorised December 8, 2016; Luveniq (lutetium-177 edotreotide), application withdrawn. Read October 5, 2026.
  4. [pubmed] Baum RP, et al. "Systematic review and meta-analysis of the efficacy and safety of [(177)Lu]Lu-edotreotide ([(177)Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors." J Neuroendocrinol, 2026;38(1):e70103. PMID: 41204752.
  5. [pubmed] Chen SH, et al. "68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan." J Formos Med Assoc, 2018;117(6):480-487. PMID: 28735662.
  6. [pubmed] Capdevila J, et al. "A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)." BMC Cancer, 2025;25(1):613. PMID: 40186126.
  7. [pubmed] Wang LF, et al. "The therapeutic efficacy of 177Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis." Medicine (Baltimore), 2020;99(10):e19304. PMID: 32150065.
  8. [pubmed] Baum RP, et al. "First-in-Humans Application of (161)Tb: A Feasibility Study Using (161)Tb-DOTATOC." J Nucl Med, 2021;62(10):1391-1397. PMID: 33547209.
  9. [pubmed] Johnbeck CB, et al. "Head-to-Head Comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors." J Nucl Med, 2017;58(3):451-457. PMID: 27660147.
  10. [pubmed] Walter T, et al. "[(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial." Lancet, 2026;408(10551):234-247. PMID: 42392118.
  11. [pubmed] Fedrigo R, et al. "Comparison of [(111)In]octreotide Scintigraphy and [(68)Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility." Neuroendocrinology, 2026;116(5):299-306. PMID: 42284283.
  12. [pubmed] Gallicchio R, et al. "Ga-68-Edotreotide PET/CT SSTR Total Tumor Volume as a Predictor of Outcome in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors." Cancer Control, 2026;33:10732748251413808. PMID: 41572131.
  13. [pubmed] Schweiger L, et al. "Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [(90)Y]Y-DOTATOC in patients with refractory meningioma: a single-centre experience." Eur J Nucl Med Mol Imaging, 2026. PMID: 42554825.
  14. [pubmed] Küper AT, et al. "SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [(68)Ga]Ga-DOTATOC and [(68)Ga]Ga-SSO120 with [(18)F]FDG PET." J Nucl Med, 2026;67(9):1413-1420. PMID: 42350034.
  15. [pubmed] Bushnell DL Jr, et al. "90Y-edotreotide for metastatic carcinoid refractory to octreotide." J Clin Oncol, 2010;28(10):1652-9. PMID: 20194865.
  16. [pubmed] Hartmann H, et al. "[Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations]." Nuklearmedizin, 2009;48(5):201-7. PMID: 19639164.
  17. [pubmed] Albers MB, et al. "Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1." World J Surg, 2017;41(6):1521-1527. PMID: 28138732.
  18. [pubmed] Wedin M, et al. "Prevalence of metastases outside the liver and abdominal lymph nodes on (68)Ga-DOTATOC-PET/CT in patients with small intestinal and pancreatic neuroendocrine tumours." J Neuroendocrinol, 2024;36(5):e13391. PMID: 38590270.
  19. [pubmed] Kim K, et al. "68Ga-DOTATOC PET/CT in the Localization of Pituitary Tumors in Cushing's Disease." Endocrinol Metab (Seoul), 2025;40(4):637-647. PMID: 40101328.
  20. [pubmed] Al-Adhami D, et al. "False Positive Findings of (68)Ga-DOTATOC PET/CT: A Systematic Review." Mol Imaging Radionucl Ther, 2025;34(3):256-266. PMID: 41058218.

Sources & Citations

Studies were read from their PubMed records; regulatory sources are listed below, read October 3, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-16